Chronic immune activation and inflammation as the cause of malignancy

por O'Byrne, K J, Dalgleish, A G
Publicado 2001

Serum vascular endothelial growth factor load and interleukin-6 in cancer patients

por O'Byrne, K J, Dobbs, N, Harris, A L
Publicado 2000

Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer

por Swinson, D E B, Cox, G, O'Byrne, K J
Publicado 2004

Targeting histone deacetylases for the treatment of disease

por Lawless, M W, Norris, S, O’Byrne, K J, Gray, S G
Publicado 2009

Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy

por Godwin, P., Baird, A. M., Heavey, S., Barr, M. P., O’Byrne, K. J., Gately, K.
Publicado 2013

Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura

por Edwards, J G, McLaren, J, Jones, J L, Waller, D A, O'Byrne, K J
Publicado 2003

Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.

por O'Byrne, K. J., Ennis, J. T., Freyne, P. J., Clancy, L. J., Prichard, J. S., Carney, D. N.
Publicado 1994

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

por O'Byrne, K J, Thomas, A L, Sharma, R A, DeCatris, M, Shields, F, Beare, S, Steward, W P
Publicado 2002

Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival.

por Koukourakis, M. I., Giatromanolaki, A., Kakolyris, S., O'Byrne, K. J., Apostolikas, N., Skarlatos, J., Gatter, K. C., Harris, A. L.
Publicado 1998

Angiogenesis is an independent prognostic factor in malignant mesothelioma

por Edwards, J G, Cox, G, Andi, A, Jones, J L, Walker, R A, Waller, D A, O'Byrne, K J
Publicado 2001

A phase II study of bryostatin 1 in metastatic malignant melanoma.

por Propper, D. J., Macaulay, V., O'Byrne, K. J., Braybrooke, J. P., Wilner, S. M., Ganesan, T. S., Talbot, D. C., Harris, A. L.
Publicado 1998

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

por O'Byrne, K J, Koukourakis, M I, Giatromanolaki, A, Cox, G, Turley, H, Steward, W P, Gatter, K, Harris, A L
Publicado 2000

Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.

por Koukourakis, M. I., Giatromanolaki, A., O'Byrne, K. J., Comley, M., Whitehouse, R. M., Talbot, D. C., Gatter, K. C., Harris, A. L.
Publicado 1997

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.

por Thompson, C. H., Macaulay, V. M., O'Byrne, K. J., Kemp, G. J., Wilner, S. M., Talbot, D. C., Harris, A. L., Radda, G. K.
Publicado 1996

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.

por O'Byrne, K. J., Koukourakis, M. I., Saunders, M. P., Salisbury, A. J., Isaacs, R., Varcoe, S., Taylor, M., Ganesan, T. S., Harris, A. L., Talbot, D. C.
Publicado 1998

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer

por O'Byrne, K J, Dobbs, N, Propper, D J, Braybrooke, J P, Koukourakis, M I, Mitchell, K, Woodhull, J, Talbot, D C, Schally, A V, Harris, A L
Publicado 1999

Phase I study of the mitomycin C analogue BMS-181174.

por Macaulay, V. M., O'Byrne, K. J., Green, J. A., Philip, P. A., McKinley, L., LaCreta, F. P., Winograd, B., Ganesan, T. S., Harris, A. L., Talbot, D. C.
Publicado 1998

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha

por Braybrooke, J P, Propper, D J, O’Byrne, K J, Koukourakis, M I, Patterson, A V, Houlbrook, S, Love, S D, Varcoe, S, Taylor, M, Ganesan, T S, Talbot, D C, Harris, A L
Publicado 2000

Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer

por Paul, I, Chacko, A D, Stasik, I, Busacca, S, Crawford, N, McCoy, F, McTavish, N, Wilson, B, Barr, M, O'Byrne, K J, Longley, D B, Fennell, D A
Publicado 2012

Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo

por Manente, A G, Valenti, D, Pinton, G, Jithesh, P V, Daga, A, Rossi, L, Gray, S G, O'Byrne, K J, Fennell, D A, Vacca, R A, Nilsson, S, Mutti, L, Moro, L
Publicado 2013